Status:
COMPLETED
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
Lead Sponsor:
Trishula Therapeutics, Inc.
Collaborating Sponsors:
AbbVie
Conditions:
Solid Tumor, Adult
Eligibility:
All Genders
18-110 years
Phase:
PHASE1
Brief Summary
This is a phase 1/1b study of TTX-030 in combination therapy, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction ...
Eligibility Criteria
Inclusion
- Abbreviated
- Age 18 years or older, is willing and able to provide informed consent
- Histologically confirmed diagnosis of unresectable or metastatic solid tumor malignancy in selected tumor types
- Life expectancy \> 12 weeks
- ECOG performance status of 0-1
- Abbreviated
Exclusion
- History of allergy or hypersensitivity to study treatment components. Patients with a history of severe hypersensitivity reaction to any monoclonal antibody.
- Use of investigational agent within 28 days prior to the first dose of study treatment and throughout the study
- Receiving high-dose systemic steroid therapy or any other form of immunosuppressive therapy
- History of severe autoimmune disease
- Uncontrolled intercurrent illness or other active malignancy requiring ongoing treatment
Key Trial Info
Start Date :
March 30 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 27 2024
Estimated Enrollment :
185 Patients enrolled
Trial Details
Trial ID
NCT04306900
Start Date
March 30 2020
End Date
March 27 2024
Last Update
July 29 2025
Active Locations (32)
Enter a location and click search to find clinical trials sorted by distance.
1
HonorHealth Research Institute
Scottsdale, Arizona, United States, 85258
2
City of Hope Medical Center Clinical Trials Office
Duarte, California, United States, 91010
3
University of Southern California
Los Angeles, California, United States, 90007
4
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048